BioSpace News Archive

Valitor today announced that data reviewing the therapeutic potential of its Multivalent Polymer (MVP) technology in oncology has been accepted for poster presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting taking place April 14-19, 2023 in Orlando, FL.

Nuvectis Pharma, Inc. today announced the initiation of the Phase 1b study for NXP800 in platinum-resistant, ARID1a-mutated ovarian carcinoma.

Ultima Genomics, Inc. and Genome Insight, Inc. have signed an agreement to collaborate to bring affordable whole genome sequencing solutions to cancer patients.

Totus Medicines announced it will be presenting four posters at the American Association for Cancer Research (AACR) Annual Meeting, regarding its lead program, TOS-358, the first highly specific, covalent PI3Kα inhibitor.

Babson Diagnostics today announced the addition of a clinical advisor who will bring valuable insights of the medical community in the ongoing development and introduction of the company’s new diagnostic blood testing service, BetterWay™. Andrew Carroll, M.D., a family physician and clinical assistant professor at the University of Arizona College of Medicine, will provide advice and counsel about clinical best practices and review validation data and reports.

Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs today announced that an abstract about CPP-1X (also known as DFMO or Eflornithine) research, has been accepted for poster presentation at the Immunology of Diabetes Society (IDS) meeting, which will be held May 23-27, 2023.

Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces the completion of a private placement of 2,030,458 shares of common stock at a price of $1.97 per share for proceeds of $4.0 million.

ABVC BioPharma, Inc. today announced that the Phase 1 Site Initiation Visit (SIV) of ABV-1601 was successfully conducted at Cedars-Sinai Medical Center (CSMC) in West Hollywood, California on March 31, 2023.

PhenomeX (Nasdaq: CELL), the functional cell biology company, today announced that Peter Silvester has been named to the PhenomeX board of directors, effective immediately.

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”) today announced that over 100 patients have been enrolled in the Company’s potentially pivotal study with their lead product candidate, Berubicin.